A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
Clinical trial NCT00520390 · COMPLETED
Trial details
- NCT number
- NCT00520390
- Sponsor
- Enzon Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.